This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Calcium channel blockers in myocardial infarction

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE have issued guidance as to the use of calcium channel blockers post myocardial infarction (1,2):

  • calcium channel blockers should not routinely be used to reduce cardiovascular risk after an MI
  • if beta-blockers are contraindicated or need to be discontinued, diltiazem or verapamil may be considered for secondary prevention in patients without pulmonary congestion or left ventricular systolic dysfunction
  • for patients who are stable after an MI, calcium channel blockers may be used to treat hypertension and/or angina
  • for patients with heart failure, amlodipine should be used, and verapamil, diltiazem and short-acting dihydropyridine agents should be avoided

Notes:

  • therapeutic trials testing the efficacy of calcium channel blockers in the management of acute myocardial infarction include the SPRINT trial.

Reference:

  1. NICE (May 2013). Secondary prevention in primary and secondary care for patients following a myocardial infarction
  2. NICE (2020). Acute coronary syndromes.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.